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Background: Clinical trials applying iota-carrageenan nasal spray have previously shown to reduce duration of
virus-confirmed common cold. The present study pooled data of two similar clinical trials to provide further
evidence for the antiviral effectiveness of carrageenan.
Methods: Individual patient data were analyzed from two randomized double blind placebo controlled trials assessing
the therapeutic effectiveness of carrageenan nasal spray in acute common cold. Patients with virus-confirmed common
cold (n = 254, verum 126, placebo 128) were included and the following parameters were appraised: duration of
disease, number of patients with relapses, number of respiratory viruses and viral titers at inclusion (visit 1) compared to
days 3–5 (visit 2).
Results: Carrageenan treated patients showed a significant reduction in duration of disease of almost 2 days (p < 0.05)
as well as significantly fewer relapses during 21 days of observation period (p < 0.05). The virus clearance between visit
1 and visit 2 was significantly more pronounced in the carrageenan group (p < 0.05). In both studies, virus-confirmed
common cold was caused by three main virus subtypes: human rhinovirus (46%), human coronavirus (25%) and
influenza A (14%) virus. Carrageenan nasal spray showed significant antiviral efficacy in all three virus subgroups, the
highest effectiveness was observed in human corona virus-infected patients. The reduced duration of disease was 3 days
(p < 0.01) and the number of relapses was three times less (p < 0.01) in carrageenan treated corona-virus-infected
patients compared to control patients.
Conclusions: Administration of carrageenan nasal spray in children as well as in adults suffering from virus-confirmed
common cold reduced duration of disease, increased viral clearance and reduced relapses of symptoms. Carrageenan
nasal spray appeared as an effective treatment of common cold in children and adults.
Trial registration: Pooled data from ISRCTN52519535 and ISRCTN80148028
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Acute viral upper respiratory tract infection, also known
as common cold, is the most frequently observed infec-
tious disease in human beings. Children get four to eight
upper respiratory infections per year and adults suffer
from two to four episodes per year [1]. In the majority
of cases common cold is caused by respiratory viruses
such as rhinovirus, coronavirus, parainfluenza, influenza,* Correspondence: tamas.fazekas@aon.at
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article, unless otherwise stated.respiratory syncytial virus, adenovirus, enterovirus and
metapneumovirus [2-4]. Although common cold is a
self-limiting disease, the symptoms such as runny nose,
nasal congestion, sneezing, cough, sore throat, malaise
and fever are troublesome, leading to more than 20
million doctor visits and 40 million lost school and work
days per year [5]. Despite the enormous economic and
social burden of common cold, an effective treatment is
still not available.
As common cold is caused by diverse viruses, an
effective therapeutic substance should exhibit a broadntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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mation. Carrageenans may represent such an option.
Carrageenans belong to a family of linear, sulfated poly-
saccharides which are found in some species of red sea-
weed. Food, cosmetic, and pharmaceutical industry use
carrageenans extensively as emulsifying and binding agent
for products like ice cream, various gels, toothpaste and
others [6]. But carrageenans also revealed antiviral activity
against a range of animal viruses [7] and are even used to
prevent sexual transmitted viral infections as a component
of spermicides [8]. Furthermore, in vitro and in vivo stud-
ies have recently shown that carrageenans are potent
inhibitors of papilloma virus [9], human rhinovirus [10],
influenza A virus [11], respiratory syncytial virus and also
of human enterovirus 71 [12].
Three randomized controlled clinical trials (RCT) showed
the superior symptomatic benefit [13] and antiviral efficacy
of carrageenan containing nasal spray [14,15] in patients
with common cold. The current study aims to provide a
deeper insight into the results of the two larger RCTs.
Carrageenan is a large polymer which does not permeate
the nasal mucosa and the antiviral effect is based on a phys-
ical mode of action only. Therefore, this host-independent
mode of action allows pooling the data from a study in
children and adults which would not be acceptable for a
substance exhibiting a pharmacological action. Subgroups
of individual viruses in the two trials were quite small, so
pooling of data allowed the analysis of subgroups of the
most frequently occurring viruses. In addition, it was inves-
tigated if the broad antiviral activity observed in vitro
against enveloped viruses (influenza and corona virus) and
non-enveloped viruses (rhinovirus) is also reflected in the
clinical data. Therefore, data of two similar trials were
merged and an additional analysis regarding the antiviral
effectiveness of carrageenan nasal spray in patients with
virus-confirmed common cold was performed.
Methods
Individual patient data from two phase III randomized,
double-blind, placebo-controlled trials were pooled for
this analysis [14,15]. Main characteristics of these trials
are given in Table 1.
Both trials were approved by Independent Ethics Commit-
tees of the participating centres and conducted according to








Fazekas T. et al.
2012 [14]
213 1-18 years Duration of
symptoms since 36 h
7 d
Ludwig M. et al.
2013 [15]
211 ≥18 years Duration of
symptoms since 48 h
7 dMain inclusion criteria in both trials were the presence
of early symptoms of common cold, with symptoms up
to 36 hours before enrollment in the children’s trial and
up to 48 hours in the adult trial. The severity of the cold
was measured using a symptom score [16]. The score was
calculated by summing 8 symptoms (headache, muscle
ache, chilliness, sore throat, nasal obstruction, nasal dis-
charge, cough, and sneezing) with each item rated 0 =
absent, 1 = mild, 2 = moderate and 3 = severe. Patients
with a symptom score of 1–9 (children’s trial) or 2–9
(adult’s trial) at the time of inclusion were enrolled in
the study. Investigators and patients were masked to
treatment and the test spray and matching placebo were
indistinguishable. Patients were randomly assigned using a
permuted block schedule (size four). After randomization,
patients received treatment with either iota-carrageenan
nasal spray (0.12% iota-carrageenan/0.5% sodium saline;
“carrageenan”) or placebo (0.9% sodium saline; “placebo”)
three times per day, for 7 days. Presence of common cold
symptoms were recorded in daily diaries till day 21 after
inclusion in trials.
Nasal lavage samples were collected on day 1 (visit 1,
V1) before the first application of the medication and
either on days 3 to 5 [14] or days 3 to 4 [15] respectively
(visit 2, V2) during treatment. In the second trial [15],
nasal lavage samples were also obtained on study days
10 or 11, after treatment. If one of the third samples was
virus positive, patients were also included into analysis.
Molecular screening and quantitative assessment of
viral load in nasal lavage samples were performed for
influenza virus types A (InfA) and B (Inf B), respiratory
syncytial virus (RSV), parainfluenza viruses (PIV) types
1–3, human rhinovirus (hRV), human metapneumovirus
(MPV), coronavirus types OC43 and 229E (hCV). A
patient was considered to be virus-positive if any virus was
detected at least in one sample. For detailed information
on the methods used see previous publications [14,15].
According to study objectives, patient data from all
virus-positive patients were included into the pooled
analysis. For the assessment of clinical effectiveness the
following parameters were determined: (1) duration of
disease and (2) number and frequency of relapses. The
duration of disease was defined as the time until the last
day with symptoms of common cold. Relapses were
defined as re-occurrence of symptoms when the patientded into efficacy analysis of carrageenan nasal spray in
n of nasal application
rageenan or placebo
Outcomes Follow-up
ays 3 times per day Symptoms severity; number of
days without symptoms; viral load
21d
ays 3 times per day Duration of disease; symptoms
severity; viral load
21d
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having reported at least one day without symptoms.
For assessment of antiviral effectiveness the following
variables were selected: (1) number of different viruses
detected at V1 and V2, (2) change of viral titers from V1
to V2 and (3) number of patients with viruses at V1 and
V2. Similar to adverse events which can occur several
times in one patient, several common cold viruses can
infect one patient at the same time. Consequently, for
the calculation of the difference of viral titers between
V1 and V2 the concept of virus events was applied, this
means that calculations are performed for each virus
individually. Gender and age were assessed as important
demographic co-variables. The analysis of these parame-
ters was performed for the virus-positive (VP) population
and for patient subgroups that were positive for a specific
virus of the most frequently detected ones (i.e., hRV, hCV
and InfA).
All findings after the screening visit were documented as
adverse effects (AEs) except for any symptoms attributed
to common cold (sneezing, runny nose, nasal obstruction,
sore throat, cough, headache, fatigue and chilliness). Never-
theless, if such symptoms were of marked intensity or
deemed to be not related to the study disease, these were
recorded as AEs.
Statistical analysis was performed using statistical IBM
software package SPSS Version 20.0. Analysis of dur-
ation of disease was done by using the log rank test. All
data sets were checked for normal distribution by theFigure 1 Distribution of patients included in the pooled analysis.Kolmogorov-Smirnov-Test prior to analysis. Binary or
categorical data (e.g. presence or absence of viruses,
number of patients with adverse events) were analysed
by the Chi-Square test. Viral titer in nasal lavage
samples and changes in viral titers between visits were
analysed using non-parametric Mann–Whitney U-test
due to the fact that the distribution of data was not
normal and in addition the data set was highly skewed.
In the dataset for this analysis, all viruses detected




In the two double-blinded randomized controlled trails
254 virus-positive patients were enrolled in the intention-
to-treat (ITT) population. Out of them, 126 patients were
randomized into carrageenan treatment, whereas 128
patients were allocated to placebo treatment. In the per-
protocol (PP) population remained 191 patients divided
in 97 patients in carrageenan group and 94 patients in
placebo group (Figure 1).
Demographic data are shown in Table 2. The virus
positive ITT population consisted of 136 females (59
carrageenan and 77 placebo) and 118 males (67 carra-
geenan and 51 placebo) (Table 2). A statistical sig-
nificant difference was recognized in distribution of
males and females in carrageenan and placebo groups
in ITT population. This difference derived mainly from
Table 2 Demographic characteristics of patients
ITT population PP population
Carrageenan Placebo Carrageenan Placebo
n = 126 % n = 128 % p n = 97 % n = 94 % p
Male 67 53 51 40 54 56 41 44
Female 59 47 77 60 0.033* 43 44 53 56 0.096
Mean SD Mean SD Mean SD Mean SD
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[14]. Nevertheless, a statistical adjustment analysis was
performed but didn’t show any difference in results
(data not shown). No distribution differences were seen
in any other patient population, e.g. PP population, or
in one of the three virus infected subgroups (data not
shown).Figure 2 Duration of common cold symptoms in ITT and PP groups. D
with carrageenan or placebo in ITT or PP population, respectively (ITT: carraDuration of symptoms and clinical effectiveness
At inclusion, intensity of common cold symptoms (symp-
tom score) was similar for carrageenan (6.42 ± 0.18) and
placebo (6.59 ± 0.16) treated patients, in ITT population
(p = 0.485). Similarly, there was no difference in PP popu-
lation in the respective groups, carrageenan (6.47 ± 0.2)
and placebo (6.43 ± 0.18). Duration of common colduration of common cold symptoms in virus-positive patients treated
geenan vs. placebo p = 0.002; PP: carrageenan vs. placebo p = 0.016).
Figure 3 Percentage of patients with relapses during the 21 days observation period. Relapses in carrageenan and placebo treated groups
presented in ITT and PP population. (* p < 0.05; ** p < 0.01).
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patients compared to placebo treated ones, in both the ITT
and the PP population. The average duration of disease
was diminished by 1.9 days in ITT carrageenan group
and by 1.7 days in PP carrageenan group compared
to the respective placebo groups (ITT: p = 0.002; PP:
p < 0.016) (Figure 2).
Relapses
During the 21 days of observation, relapses were observed
significantly more frequently in placebo groups than in
carrageenan treated patients, irrespectively of ITT or PP
population (ITT: p = 0.003; PP: p = 0.01) (Figure 3). As
some patients had more than one relapse during observa-
tion period, the average number of relapses per patient
was calculated. The average number of relapses per
patient was 0.17 in carrageenan treated patients compared
to 0.45 in placebo treated patients in ITT population
(p = 0.002). Likewise, the average number of relapses
per patient was significantly higher in placebo group,
namely 0.38 compared to 0.15 in carrageenan group in
PP population during observation period (p = 0.01).
Analysis of antiviral efficacy
For the analysis of antiviral effectiveness, patients who
were virus-positive on visit 1 (day 1), visit 2 (days 3–5) or
on both visits were included. Patients who missed visit 2
were excluded from the analysis because of incomplete
data. Each detected virus was taken as a separate event. At
inclusion, irrespectively of ITT or PP population, averageviral titers (measured as log[x + 1]) of obtained real time
PCR copy numbers were similar in carrageenan (ITT:
4.82 ± 0.2; PP: 4.42 ± 0.2) and placebo (ITT: 4.42 ± 0.2; PP:
4.66 ± 0.2) groups. A significant decrease in viral titers was
observed at visit two in all groups. However, in ITT popu-
lation the decrease in viral titers was significantly more
prominent in carrageenan group (−2.2 log[x + 1]) than in
placebo group (−1.1 log[x + 1]; p = 0.022). The data in-
dicated that treatment with iota-carrageenan resulted
in a reduction of viral titer at visit 2 which was an order
of magnitude of more than 90% stronger when com-
pared with placebo treatment. Similarly, the difference
in virus titers between visit 1 and visit 2 was signifi-
cantly higher in carrageenan group compared to placebo
group in PP population (carrageenan: −2.25, placebo: −1.2;
p = 0.044) (Table 3).
Since in some patients more than one virus was de-
tected, treatment groups were compared with regard to
number of viruses per patient on visits 1 and 2. Whereas
at baseline, groups did not differ significantly, at visit 2
numbers of viruses per patient were significantly lower
in the carrageenan group. Accordingly, the change in
the number of viruses per patient between visit 2 and
visit 1 was more pronounced in the carrageenan group:
on average, a placebo patient cleared 0.15 ± 0.07 viruses,
while carrageenan treated patients lost 0.37 ± 0.07 viruses
in ITT population (p = 0.02). Similarly, in PP population
virus clearance was 0.14 ± 0.7 in placebo group versus
0.38 ± 0.7 in carrageenan group (p = 0.025). In carrageenan
treated patients a significant increase of virus-free patients

















(Mann- Whitney U- test)
ITT Verum (n = 116) 154 V1 4.64 (3.41;6.57)
p = 0.022
Verum (n = 116) 154 V2 3.61 (0;4.97) p < 0.001 −2.2 (−3.47;-0.26)
Placebo (n = 120) 163 V1 4.49 (3.24;6.3)
Placebo (n = 120) 163 V2 3.82 (0;4.85) p < 0.001 −1.14 (−3.31;0.31)
PP Verum (n = 87) 115 V1 4.66 (3.4;6.54)
p = 0.044
Verum (n = 87) 115 V2 3.63 (0;4.83) p < 0.001 −2.25 (−3.47;-0.57)
Placebo (n = 87) 113 V1 4.99 (3.35;6.49)
Placebo (n = 87) 113 V2 3.98 (2.24;4.89) p < 0.001 −1.2 (−3.24;0.21)
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in PP population. In contrast, placebo treated patients
showed no difference in virus-free individuals between
visit 1 and visit 2 (Table 4). Figure 4 shows the percentage
of patients with either a deterioration (defined as > 50-fold
increase of viral titer at visit 2 or detection of a new
virus which was not revealed at visit 1) an improvement
(defined as a >50-fold decrease of viral titer at visit 2
or the elimination of a virus which was present at visit
1) or no change (defined as a viral titer between 1:50
to 50:1 at visit 2 compared to visit 1) in virus status be-
tween visit 1 and visit 2. Significantly more patients re-
vealed an improvement in viral status between visit 1
and visit 2 in carrageenan treated patients compared to
placebo treated ones, in ITT as well as in PP population.
(ITT: p = 0.005; PP: p = 0.009, Figure 4).
In the two pooled studies the following viruses were
detected most frequently: hRV (142 patients), hCV
(types OC43 or 229E, 78 patients) and InfA (43 pa-
tients). Patients positive for different viral types were
distributed evenly between carrageenan and placebo
treatment arms (Table 5).
Subgroup analysis was done for the three most com-
mon virus types in the pooled population, hRV, hCV and
InfA virus, respectively. In the ITT population, the dur-
ation of common cold disease was significantly reduced in
all three virus subgroups treated with carrageenan. This
effect was most pronounced in hCV infected patients
treated with carrageenan where the reduction of durationTable 4 Change in number of virus-free patients from visit 1
Patients Group Viru
ITT (n = 236) Placebo (n = 120)
Carrageenan (n = 116)
PP (n = 174) Placebo (n = 87)
Carrageenan (n = 87)
McNemar test within-group comparison.was almost 4 days in ITT population (p < 0.01) and 3 days
in PP population (p < 0.01) (Table 6 and Figure 5).
In all three virus subgroups, a significant reduction in
duration of common cold was recorded in carrageenan
treated patients compared to placebo ones in ITT popu-
lation. Similarly, a significant reduction was seen in PP
population between carrageenan and placebo groups
except for InfA patients.
Relapses in subgroups
Relapses occurred significantly more frequently in placebo
groups of hRV and hCV infected patients compared to
carrageenan group, in ITT population. Similarly, in InfA
infected patients a trend to more relapses was observed in
placebo group (p = 0.055) (Figure 6A). Also in the PP popu-
lation, a higher percentage of relapses was noticed in
placebo treated virus infected subgroups. However, only in
hCV infected patients this difference reached statistical
significance (p = 0.005) (Figure 6B). In the ITT population,
the average number of relapses per patient was significantly
lower in carrageenan treated virus-infected subgroups. Thus,
in hRV infected patients, the average number of relapses per
patient was 0.13 in carrageenan treated patients and 0.79 in
placebo treated ones (p = 0.04). In hCV infected patients
relapses per patient occurred 0.2 times in carrageenan
treated patients compared with 0.58 times in placebo treated
ones (p = 0.007). Moreover, placebo treated InfA infected
patients had 0.79 relapses per patient compared to 0.13
relapses per patient in carrageenan group (p = 0.04).to visit 2 in ITT and PP population
s acquired Virus lost Significance
11 (9%) 18 (15%) n.s.
4 (3%) 27 (23%) p < 0.001
5 (6%) 12 (14%) n.s.
3 (3%) 20 (23%) p < 0.001
Figure 4 (See legend on next page.)
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Figure 4 Percentage of patients with dynamic changes in viral status between visit 1 and visit 2. “Deterioration” was defined as > 50-fold
increase of viral titer at visit 2 or detection of a new virus which was not revealed at visit 1. “Improvement” was defined as a > 50-fold decrease
of viral titer at visit 2 or the elimination of a virus which was present at visit 1. “No change” was defined as a viral titer between 1:50 to 50:1 at visit
2 compared to visit 1. A: a ITT population p = 0.005 B: PP population p = 0.009.
Table 6 The average duration of common cold disease in
patients of different virus subgroups in days
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average number of relapses per patient was recognized
in all virus infected subgroups but solely in hCV infected
subpopulation this difference reached significance (0.18
versus 0.53, p = 0.006).
Safety
Overall tolerability of study products was very good and
there was no difference between treatment arms in the
number of patients with AEs or severe adverse events
(SAEs) (Table 7). About 80% of patients did not report any
AE until the end of the observation period. Interestingly,
rhinitis (newly diagnosed cases and deterioration of the
condition during the study) was observed more frequently
in the placebo group (no case in carrageenan treatment
arm compared to 4 cases in placebo), with a statistically
significant difference between groups (p = 0.045). In the
two studies six patients experienced SAEs, none of them
was study related and all SAEs resolved until the end of
the study. All AEs were rated as not-study-related.
Discussion
In the present study data from two randomized con-
trolled clinical trials, investigating the effectiveness of
carrageenan nasal spray during virus-confirmed com-
mon cold, were analyzed. This analysis showed that
carrageenan-containing nasal spray reduced the duration
of viral-confirmed common cold by almost 2 days. Fur-
thermore, carrageenan-treated patients cleared more
than twice as many viruses when compared to placebo-
treated patients. Additionally, more virus-free patients
were found in carrageenan-treated patients at visit 2.
Another clinical benefit of carrageenan nasal spray was
the significant reduction in relapses defined as recur-
rence of symptoms after a patient was free of symptoms
for at least one day.
Annually common colds account for more than 20
million doctor visits and 40 million lost school and work
days in the USA alone [5]. It is the most frequentlyTable 5 Percentage of patients being positive for
different types of viruses in ITT population
Virus
Group hRV hCV** InfA InfB MPV PIV*** RSV Total
Verum 45 % 27 % 13 % 5 % 6 % 2 % 2 % 145
Placebo 47 % 24 % 14 % 7 % 6 % 2 % 1 % 161
**Patients positive for hCV OC43 or 229E or both.
***Patients positive for PIV types 1, 2 or 3.observed infectious disease in human beings, with four
to eight episodes per year in children and three to five in
adults [1,17]. Therefore, a reduction of disease duration
by 2 days has an enormous impact on economic losses
and social welfare of children and their families.
Common cold is mainly caused by respiratory viruses,
such as human rhinovirus, human coronavirus, para-
influenza, influenza, respiratory syncytial virus, adeno-
virus, enterovirus and metapneumovirus [4,5,18,19].
Since it is impossible for an individual to determine the
cause of a cold, it is important to know if the product
used provides effectiveness against many different re-
spiratory viruses causing colds. In the present study, the
analysis of virus species revealed that human rhinovirus,
human coronavirus and influenza A virus were the most
common species. Nasal administration of carrageenan
during common cold episodes consistently showed a
reduction in duration of disease in patient subgroups
infected with these three viruses. The decrease in duration
of disease varied between 1.9 days for rhinovirus up to
3.9 days for coronavirus with infA lying in between with a
reduction of 3.3 days (Table 6). The study data suggest
that carrageenan nasal spray exerts an unspecific effect on
viruses of different etiologic origin, both enveloped and
non-enveloped viruses. Experimental data support this
notion showing that carrageenan exhibited a potent
inhibitory effect on papilloma virus [9]. Moreover, in vitro
and in vivo studies revealed that carrageenan was effective
against several human respiratory viruses such as influ-
enza A [11] human rhinovirus [10], respiratory syncytial
virus and also of human enterovirus 71 [12]. It was shown
that the carrageenan polymer directly bound to the virus
and prevented attachment of virus to the cells [11]. Hence,
carrageenan works via an unspecific physical mode of
action at a very early stage of virus life cycle.Patients Group hRV hCV InfA
ITT Carrageenan 8.8 ± 0.6 9.02 ± 0.7 8.7 ± 1.0
Placebo 10.7 ± 0.7 12.95 ± 0.99 12.0 ± 1.2
Difference 1.9 days* 3.9 days** 3.3 days*
PP Carageenan 8.7 ± 0.7 9.1 ± 0.7 9 ± 1.1
Placebo 10.5 ± 0.8 12.2 ± 1.1 10.7 ± 1.5
Difference 1.8 days* 3.1 days** 1.7 days
*:p < 0.05; **:p < 0.01.
Figure 5 Duration of common cold in carrageenan or placebo treated patients in hRV, hCV and InfA subpopulation. A: Duration of
common cold in ITT group (p = 0.019; p = 0.001; p = 0.02, respectively). B: Duration of common cold symptoms in carrageenan or placebo treated
patients in hRV, hCV and InfA subpopulation in PP group (p = 0.041; p = 0.009; p = 0.27; respectively).
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Figure 6 Percentage of patients suffering from a relapse during 21 days of observation period. A: ITT population (hRV: carrageenan n = 70,
placebo n = 80; hCV: carrageenan n = 45, placebo n = 43; InfA: carrageenan n = 45, placebo n = 43) B: PP population (hRV: carrageenan n = 52, placebo
n = 60; hCV: carrageenan n = 38, placebo n = 32; InfA: carrageenan n = 19, placebo n = 15).
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Table 7 Overview of most commonly reported AEs
Carrageenan (n = 126) Placebo (n = 128) Total (n = 254)
n % n % n %
N. of patients without AEs 103 81,7% 99 77,3% 202 79,5%
Cough 1 0,8% 4 3,1% 5 2,0%
Rhinitis* 0 0,0% 4 3,1% 4 1,6%
Otitis media 3 2,4% 1 0,8% 4 1,6%
Nasal bleeding 3 2,4% 1 0,8% 4 1,6%
Fever, infection NOS** 2 1,6% 2 1,6% 4 1,6%
Bronchitis 2 1,6% 2 1,6% 4 1,6%
Nasal disorders NOS*** 1 0,8% 2 1,6% 3 1,2%
Vomiting 1 0,8% 1 0,8% 2 0,8%
Tonsillitis 2 1,6% 0 0,0% 2 0,8%
Sinusitis 0 0,0% 2 1,6% 2 0,8%
Rash 0 0,0% 2 1,6% 2 0,8%
Nausea 0 0,0% 2 1,6% 2 0,8%
Ear pain 1 0,8% 1 0,8% 2 0,8%
Conjunctivitis 1 0,8% 1 0,8% 2 0,8%
Adenoids 1 0,8% 1 0,8% 2 0,8%
Abdominal pain 1 0,8% 1 0,8% 2 0,8%
*Difference between groups statistically significant, p = 0.045.
**Including pyrexia, febrile infection and viral infection (not specified).
***Including nasal itching, feeling of burning in the nose and smell disturbance.
NOS = not specified.
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decrease in viral titers between visit 1 and visit 2 in
carrageenan-treated and in placebo-treated patients was
expected. But carrageenan-treated patients cleared more
than twice as many viruses compared to placebo-treated
patients leading to more virus-free patients at visit 2 in
carrageenan group (Table 4). It can be concluded that
treatment with iota-carrageenan results in a significant
reduction of the viral load and the number of detectable
viruses already at days 3–7 (V2). Absence of viruses leads
to a faster recovery and hence earlier clearance of
symptoms. These data are in line with the results of
all currently available clinical trials regarding iota-
carrageenan-treatment during common cold [13-15].
A further benefit of carrageenan treatment was the
significant reduction in relapses defined as recurrence
of symptoms after a patient was free of symptoms for
at least one day (Figure 3). Because most relapses took
place after cessation of treatment a prophylactic effect
of carrageenan nasal spray could be hypothesized.
Similarly to all virus positive patients, relapses were
reduced by carrageenan nasal spray in all three virus-
infected patient subgroups. Again, patients infected
with human coronavirus benefited most from carrageenan
treatment showing a 2.5-fold reduction in relapses com-
pared to placebo (Figure 6). Human rhinovirus infectedpatients as well as influenza A infected patients revealed a
twofold reduction in relapses when treated with carra-
geenan nasal spray.
The reduction of relapses and the reduction of virus
titer in carrageenan treated patients might be of interest
in particular patient subgroups with underlying diseases
such as asthma and COPD. Numerous recent reviews
discuss the presence of respiratory viruses as cause of
exacerbations of asthma and COPD [20-22]. Acute exac-
erbations are associated with decreased lung growth in
children or accelerated loss of lung function and, as
such, add substantially to both the cost and morbidity
associated with asthma [23]. Therefore, a reduction of
virus load and persistence should have a beneficial effect
for these patients. Especially children who frequently
suffer from viral infections often involving more than
one virus could benefit from the carrageenan nasal
spray. Due to the physical mode of action and the favor-
able side effect profile, it could be used as a cost-effective
long time preventive measure. The cost for treatment lies
below one dollar per day. Further clinical studies should
be done to investigate the prophylactic effect of the carra-
geenan nasal spray in patients with respiratory diseases as
well as other patients groups where the prevention of viral
infections is of utmost importance (e.g. cancer patients,
immunocompromised patients).
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http://www.mrmjournal.com/content/9/1/57The limitations of this study include the retrospective
nature of the data analysis, while some additional clinical
information of the patients would have been necessary
for underlining our findings. Furthermore, the clinical
benefit of using carrageenan nasally was not measured
e.g. by spirometry. However, in small children included
in the data set, it is not always possible to perform spiro-
metric measurements.
Conclusions
In conclusion, nasal application of carrageenan spray in
children as well as in adults suffering from virus-confirmed
common cold reduced duration of disease, increased viral
clearance and reduced relapses. Therefore, carrageenan
nasal spray can be regarded as a safe and effective treat-
ment with a high potential for reducing social and eco-
nomic burden caused by common cold.
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